Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.

doi:10.1200/PO-25-00119

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.

JCO precision oncology - 1 Oct 2025

Tsao Anne S, Song Zihe, Ho Alan L, Mehnert Janice M, Ivy Percy, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David R, Williams P Mickey, Hamilton Stanley R, Takebe Naoko, Ajumally Raid, Silhavy Jennifer, Rahmanian Sorena, Das Biswajit, Chen Li, Karlovich Chris, Lococo Jennifer S, Tricoli James V, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith T

Abstract excerpt

PURPOSE: The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) (EAY131, ClinicalTrials.gov identifier: NCT02465060) trial pairs patients with targeted therapies on the basis of tumor genomic alterations. Subprotocol T assessed vismodegib, a hedgehog pathway inhibitor, in patients with Patched-1 (PTCH1) and Smoothened (SMO) alterations (excluding basal cell carcinoma). METHODS: Eligible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Anilides

Share to Antineoplastic Agents

Share to Neoplasms

Share to Patched-1 Receptor

Share to Pyridines

Share to Smoothened Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 41066729
DOI: 10.1200/PO-25-00119
PMCID: PMC13488493

Genes

PTCH1
SMO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.PMID 41066729Read ↗

Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastomaSemantic proximity Read ↗

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032Semantic proximity Read ↗

Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment.Semantic proximity Read ↗

Chondrosarcoma Organoids Reveal Targetable SHH Pathway Activation via PTCH1 AlterationsSemantic proximity Read ↗

Establishment of a patient-derived malignant peripheral nerve sheath tumor organoid model reveals SHH pathway activation and therapeutic vulnerabilitySemantic proximity Read ↗

Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult MedulloblastomaSemantic proximity Read ↗

Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey.Semantic proximity Read ↗

Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinomaSemantic proximity Read ↗

Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer TherapySemantic proximity Read ↗

Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.Semantic proximity Read ↗

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.Semantic proximity Read ↗

Study protocol: Sonidegib for Nevoid Basal Cell Carcinoma (Gorlin) Syndrome and EADO stage IIb Sporadic BCC, a phase II Study (SIBLINGS TRIAL).EU CT n. 2024-515989-14-00Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.